BAKU, Azerbaijan, Sept. 30
By Fakhri Vakilov – Trend:
Uzbekistan’s Jurabek Laboratories JV LLC produced 1,458,820 doses of ZF-UZ-VAC2001 coronavirus vaccine which were transferred to representatives of the Sanitary-Epidemiological Surveillance and Health Service of Uzbekistan on September 30, Trend reports citing Vaccination.uz portal.
To date, the facility has produced a total of 7 million doses of vaccine.
According to the results of phase III clinical trials, the effectiveness of the ZF-UZ-VAC2001 vaccine is 81.76 percent after 3 doses for all types of coronavirus and 92.93 percent against the "UK" type of COVID-19.
Jurabek Laboratories JV LLC produces this vaccine under a cooperation agreement signed with the Chinese company Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
The ZV-UZ-VAC2001 COVID-19 vaccine was developed by Zhifei Longcom Biopharmaceutical in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences, the Center for Advanced Technologies under the Ministry of Innovation of Uzbekistan and the Research Institute of Virology of the Ministry of Health of Uzbekistan.
Follow author on Twitter:@vakilovfaxri